2022 Annual Meeting Virtual Experience | PL1 - Presidential Plenary Session

Date Sunday 04/24/22

Time 10:00 AM - 12:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) Natalia S. Rost, MD, MPH, FAHA, FAAN

Topic(s) Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, General Neurology, Health Care Disparities

Learning Objectives This session features the AAN's premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant neurology findings in 2022.

CME Available 2.50 CME credits

Program Materials Program Evaluations

Event Timeline
10:00 AM - 10:05 AM EDT	Introduction	Introduction Natalia S. Rost, MD, MPH, FAHA, FAAN
10:05 AM - 10:35 AM EDT	Speaker	George C. Cotzias Lecture: Autism and Genetics Daniel H. Geschwind, MD, PhD
10:35 AM - 10:40 AM EDT	Introduction	Introduction Natalia S. Rost, MD, MPH, FAHA, FAAN
10:40 AM - 11:10 AM EDT	Speaker	Sidney Carter Award in Child Neurology: Vascular Pediatrics Catherine M. Amlie-Lefond, MD, FAAN
11:10 AM - 11:15 AM EDT	Introduction	Introduction Natalia S. Rost, MD, MPH, FAHA, FAAN
11:15 AM - 11:45 AM EDT	Speaker	Robert Wartenberg Lecture: Leaving No One Behind: Charting the Course to Cerebrovascular Health Equity Bruce I. Ovbiagele, MD, MSc, FAAN
11:45 AM - 12:30 PM EDT	Q&A	Fireside Chat Bruce I. Ovbiagele, MD, MSc, FAAN, Natalia S. Rost, MD, MPH, FAHA, FAAN, Daniel H. Geschwind, MD, PhD, Catherine M. Amlie-Lefond, MD, FAAN

Faculty Disclosures
Natalia S. Rost, MD, MPH, FAHA, FAAN	Dr. Rost has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for American Academy of Neurology. Dr. Rost has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke - AHA/ASA Journal. The institution of Dr. Rost has received research support from NIH. Dr. Rost has received publishing royalties from a publication relating to health care.
Bruce I. Ovbiagele, MD, MSc, FAAN	Dr. Ovbiagele has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Stroke Association. Dr. Ovbiagele has received research support from National Institutes of Health. Dr. Ovbiagele has a non-compensated relationship as a President with Society for Equity Neuroscience that is relevant to AAN interests or activities. Dr. Ovbiagele has a non-compensated relationship as a Board Member with World Stroke Organization that is relevant to AAN interests or activities.
Daniel H. Geschwind, MD, PhD	Dr. Geschwind has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Ovid Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axial Biotherapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Falcon Computing. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier-Biological Psychiatry. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NYAS. Dr. Geschwind has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Covington& Burling LLP. Dr. Geschwind has stock in none related to talk. The institution of Dr. Geschwind has received research support from CurePSP. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from Rainwater Charitable Foundation. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from The Simons Foundation. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS/NIA. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NIH/NINDS. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from U of Virginia and NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from NIH/NHGRI. The institution of Dr. Geschwind has received research support from NIH/NIMH. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care.
Catherine M. Amlie-Lefond, MD, FAAN	Dr. Amlie-Lefond has nothing to disclose.